The use of current knowledge and non-invasive testing modalities for predicting at-risk nonalcoholic steatohepatitis and assessing fibrosis

This expert review proposes a clinical care pathway for suspected NAFLD, positioning cT1 as the key individual biomarker to risk-stratify patients and flag high-risk NASH to facilitate timely management. It further suggests that cT1 could replace or precede liver biopsy in all patients at intermediate/high risk of fibrosis, subject to hepatologist judgment.